A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours

European Journal of Cancer

Volumn 50, Issue 5, 2014, Pages 876-884

  Hollebecque, Antoine ^a   Houédé, Nadine ^b   Cohen, Ezra E W ^c   Massard, Christophe ^a   Italiano, Antoine ^b   Westwood, Paul ^d   Bumgardner, William ^d   Miller, Joel ^d   Brail, Les H ^d   Benhadji, Karim A ^d   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT BERGONIÉ   (France)

^c UNIVERSITY OF CHICAGO   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Erlotinib; Everolimus; LY2584702 tosylate; p70 S6 kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 5; ERLOTINIB; EVEROLIMUS; LY 2584702; S6 KINASE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLOOD CLOTTING DISORDER; CANCER PATIENT; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; GASTRITIS; HUMAN; HYPOPHOSPHATEMIA; INTERNATIONAL NORMALIZED RATIO; INTERSTITIAL LUNG DISEASE; LUNG EMBOLISM; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; ORAL MUCOSITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; STUDY; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ERLOTINIB; EVEROLIMUS; LY2584702 TOSYLATE; P70 S6 KINASE INHIBITOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; PYRIMIDINES; QUINAZOLINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 84896716005     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.12.006     Document Type: Article

References (20)

1. J. Huang, and B.D. Manning A complex interplay between Akt, TSC2 and the two mTOR complexes Biochem Soc Trans 37 Pt 1 2009 217 222
2. N.C. Barbet, U. Schneider, and S.B. Helliwell et al. TOR controls translation initiation and early G1 progression in yeast Mol Biol Cell 7 1 1996 25 42
3. G.J. Brunn, C.C. Hudson, and A. Sekulic et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin Science 277 5322 1997 99 101
4. N.V. Dorrello, A. Peschiaroli, and D. Guardavaccaro et al. S6K1-and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth Science 314 5798 2006 467 471
5. A.C. Gingras, B. Raught, and N. Sonenberg EIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation Annu Rev Biochem 68 1999 913 963
6. S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 3 2006 471 484
7. B. Raught, F. Peiretti, and A.C. Gingras et al. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases EMBO J 23 8 2004 1761 1769
8. S.G. Dann, A. Selvaraj, and G. Thomas MTOR complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer Trends Mol Med 13 6 2007 252 259
9. A. Tolcher, J. Goldman, A. Patnaik, and K.P. Papadopoulos et al. A phase I trial of LY2584702, a p70 S6 kinase inhibitor, in patients with advanced solid tumours Eur J Cancer 50 5 2014 867 875
10. M. Guba, M. Yezhelyev, and M.E. Eichhorn et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF Blood 105 11 2005 4463 4469
11. X.F. Ming, A.G. Rajapakse, and J.M. Carvas et al. Opposing and uncoupling effects of mTOR and S6K1 in the regulation of endothelial tissue factor expression FEBS Lett 584 1 2010 135 140
12. K. Masago, Y. Togashi, and M. Fukudo et al. Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion Clin Lung Cancer 12 5 2011 307 312
13. C.L. O'Bryant, P. Haluska, and L. Rosen et al. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function Cancer Chemother Pharmacol 69 3 2012 605 612
14. Y. Togashi, K. Masago, and M. Fukudo et al. Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis J Thorac Oncol 5 5 2010 601 605
15. M.D. Prados, K.R. Lamborn, and S. Chang et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma Neuro-oncol 8 1 2006 67 78
16. E. Van Cutsem, C. Verslype, and P. Beale et al. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients Ann Oncol 19 2 2008 332 339
17. C.M. Rudin, W. Liu, and A. Desai et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity J Clin Oncol 26 7 2008 1119 1127
18. P. Frohna, J. Lu, and S. Eppler et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects J Clin Pharmacol 46 3 2006 282 290
19. G. Jerusalem, A. Fasolo, and V. Dieras et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer Breast Cancer Res Treat 125 2 2011 447 455
20. B. Xu, Y. Wu, and L. Shen et al. Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors J Hematol Oncol 4 2011 3